Delving into the Latest Updates on EyeD Pharma SA with Synapse

Overview

Basic Info

Introduction

EyeD Pharma is a specialized pharmaceutical company committed to creating cutting-edge drug products for the field of ophthalmology. Their primary focus is on developing treatments for glaucoma.

Tags

Eye Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

No Data

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Top 5 Drug Type	Count

Small molecule drug	3

Top 5 Target	Count

β-adrenoceptors(Beta adrenergic receptors)	1

The purpose of this study is to test a new method to deliver an approved medicine called Timolol in the eye of participants with glaucoma and pseudophakia (currently present or to be performed during the concomitant implantation surgery in subjects with age-related cataract eligible to intra-capsular IOL placement). The main questions it aims to answer are how safe the investigational drug is and how the body tolerates it.
The study will also check:
* how safely the implant is placed in and removed from the eye and how the body responds to the procedure,
* how safe different doses of timolol are and how the body handles taking it,
* the amount of Timolol released in the bloodstream,
* if there is any positive effect on the pressure inside the eye.

Start Date01 Mar 2023

Sponsor / Collaborator

EyeD Pharma SA

100 Clinical Results associated with EyeD Pharma SA

Login to view more data

0 Patents (Medical) associated with EyeD Pharma SA

Login to view more data

100 Deals associated with EyeD Pharma SA

Login to view more data

100 Translational Medicine associated with EyeD Pharma SA

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 08 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

Preclinical

Phase 1 Clinical

1

2

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

TimoD ( β-adrenoceptors )	Glaucoma More	Phase 1
HydraD	Xerophthalmia More	Preclinical
BimatoD	Glaucoma More	Discovery
InflammaD	Post procedural inflammation More	Pending
ComboD	Glaucoma More	Pending